Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced today that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.
The HCPCS code #A6248 provides for 80% reimbursement of $17.05 per ounce. Reimbursement is provided for up to three ounces per month per patient wound.
"Oculus is pleased with this Medicare reimbursement coding, which affirms that national payers understand the essential role that the new Microcyn HydroGel can play in the treatment of various wound types,” said Jim Schutz, Oculus chief operating officer. “This reimbursement will provide an incentive for hospitals and clinics to more quickly integrate the Microcyn HydroGel into their treatment protocols.”